Exelixis, Inc. (EXEL): Price and Financial Metrics


Exelixis, Inc. (EXEL): $20.35

-0.15 (-0.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EXEL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

EXEL POWR Grades


  • Value is the dimension where EXEL ranks best; there it ranks ahead of 97.48% of US stocks.
  • EXEL's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • EXEL's current lowest rank is in the Momentum metric (where it is better than 9.5% of US stocks).

EXEL Stock Summary

  • EXEL's current price/earnings ratio is 68.68, which is higher than 87.71% of US stocks with positive earnings.
  • The ratio of debt to operating expenses for Exelixis Inc is higher than it is for about just 9.64% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.15 for Exelixis Inc; that's greater than it is for just 9.92% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Exelixis Inc are XLRN, ACET, ONCT, FOLD, and CLSD.
  • Visit EXEL's SEC page to see the company's official filings. To visit the company's web site, go to www.exelixis.com.

EXEL Valuation Summary

  • In comparison to the median Healthcare stock, EXEL's EV/EBIT ratio is 69.28% higher, now standing at 49.6.
  • Over the past 243 months, EXEL's price/sales ratio has gone down 21.5.
  • EXEL's price/earnings ratio has moved up 72.6 over the prior 243 months.

Below are key valuation metrics over time for EXEL.

Stock Date P/S P/B P/E EV/EBIT
EXEL 2021-08-31 5.2 3.0 64.2 49.6
EXEL 2021-08-30 5.2 3.0 64.5 49.8
EXEL 2021-08-27 5.3 3.0 65.1 50.3
EXEL 2021-08-26 5.2 2.9 63.8 49.2
EXEL 2021-08-25 5.2 2.9 63.4 48.8
EXEL 2021-08-24 5.2 2.9 63.4 48.9

EXEL Growth Metrics

  • The 2 year cash and equivalents growth rate now stands at 53.47%.
  • Its year over year net income to common stockholders growth rate is now at -77.96%.
  • The 3 year cash and equivalents growth rate now stands at 35.05%.
EXEL's revenue has moved up $1,121,964,000 over the prior 70 months.

The table below shows EXEL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 1,156.551 272.276 94.041
2021-03-31 1,030.853 192.452 64.77
2020-12-31 987.538 208.982 111.781
2020-09-30 957.796 333.71 152.136
2020-06-30 998.407 391.386 281.628
2020-03-31 979.203 421.437 293.849

EXEL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EXEL has a Quality Grade of B, ranking ahead of 92.27% of graded US stocks.
  • EXEL's asset turnover comes in at 0.525 -- ranking 305th of 556 Business Services stocks.
  • QNST, QMCI, and FPAY are the stocks whose asset turnover ratios are most correlated with EXEL.

The table below shows EXEL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.525 0.960 0.071
2021-03-31 0.486 0.961 0.045
2020-12-31 0.479 0.963 0.088
2020-09-30 0.479 0.961 0.129
2020-06-30 0.520 0.963 0.248
2020-03-31 0.539 0.964 0.273

EXEL Price Target

For more insight on analysts targets of EXEL, see our EXEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $31.77 Average Broker Recommendation 1.5 (Moderate Buy)

EXEL Stock Price Chart Interactive Chart >

Price chart for EXEL

EXEL Price/Volume Stats

Current price $20.35 52-week high $25.77
Prev. close $20.50 52-week low $16.19
Day low $20.19 Volume 913,500
Day high $20.49 Avg. volume 2,115,750
50-day MA $18.51 Dividend yield N/A
200-day MA $21.37 Market Cap 6.41B

Exelixis, Inc. (EXEL) Company Bio


Exelixis is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. The company was founded in 1994 and is based in San Francisco, California.


EXEL Latest News Stream


Event/Time News Detail
Loading, please wait...

EXEL Latest Social Stream


Loading social stream, please wait...

View Full EXEL Social Stream

Latest EXEL News From Around the Web

Below are the latest news stories about Exelixis Inc that investors may wish to consider to help them evaluate EXEL as an investment opportunity.

Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA

Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.

Yahoo | September 22, 2021

Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer

Exelixis (EXEL) gets FDA approval for a label expansion of Cabometyx for the treatment of locally advanced or metastatic differentiated thyroid cancer.

Yahoo | September 20, 2021

Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021

ALAMEDA, Calif., September 20, 2021--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX® (cabozantinib) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC). Following a previous announcement that the trial met one of the two primary endpoints of significant improvement versus placebo in progression-free survival (PFS) assessed by blinded independent radiology committee (BIRC; p<0.000

Yahoo | September 20, 2021

The 3.8% return this week takes Exelixis' (NASDAQ:EXEL) shareholders five-year gains to 39%

The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...

Yahoo | September 20, 2021

Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021

ALAMEDA, Calif., September 18, 2021--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX®) in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer (CRPC). Cohort 6 included patients with metastatic CRPC who had been previously treated with the novel hormone therapies (NHT) enzalutamide and/or abiraterone acetate used along with prednisone. The data are being

Yahoo | September 18, 2021

Read More 'EXEL' Stories Here

EXEL Price Returns

1-mo 7.62%
3-mo -13.11%
6-mo -10.31%
1-year -12.44%
3-year 18.45%
5-year 36.67%
YTD 1.40%
2020 13.90%
2019 -10.42%
2018 -35.30%
2017 103.89%
2016 164.36%

Continue Researching EXEL

Here are a few links from around the web to help you further your research on Exelixis Inc's stock as an investment opportunity:

Exelixis Inc (EXEL) Stock Price | Nasdaq
Exelixis Inc (EXEL) Stock Quote, History and News - Yahoo Finance
Exelixis Inc (EXEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9301 seconds.